Cullinan Therapeutics, Inc.
Zipalertinib
EGFR ex20ins NSCLC
Countdown
235days
FDA decision · Feb 27, 2027
What's at stake
The FDA's approval decision on Zipalertinib for EGFR ex20ins NSCLC is due Feb 27, 2027. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“The Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027.”